{"id":"uvadex","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","category":"company"}],"phase":"marketed","safety":{"boxedWarnings":["UVADEX ® (methoxsalen) Sterile Solution should be used only by physicians who have special competence in the diagnosis and treatment of cutaneous T-cell lymphoma and who have special training and experience in the THERAKOS ® CELLEX ® Photopheresis System. Please consult the CELLEX ® Operator's Manual before using this product."],"commonSideEffects":[{"effect":"Hypotension","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Dysgeusia","drugRate":"","severity":"common","organSystem":""},{"effect":"Photosensitivity reaction","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Cardiovascular adverse experiences","drugRate":"10%","severity":"serious"},{"effect":"Arrhythmia","drugRate":"2%","severity":"serious"},{"effect":"Infection","drugRate":"9.8%","severity":"serious"},{"effect":"Hickman catheter infection","drugRate":"2%","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Hypersensitivity reaction","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["8-mop"],"company":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=UVADEX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:23:17.425208+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:23:22.831556+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=UVADEX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:23:23.126806+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:23:24.294548+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL416/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:23:23.910506+00:00"}},"allNames":["uvadex"],"offLabel":[],"synonyms":[],"timeline":[],"aiSummary":"Uvadex is a small molecule drug developed by the London Health Sciences Centre Research Institute or Lawson Research Institute of St. Joseph's. However, due to the lack of available information, its target, drug class, and approved indications are unknown. Uvadex is not FDA-approved, and its commercial status, generic manufacturers, and patent status are also unclear. As a result, there is limited information available on its safety profile and key considerations. Further research is needed to understand the properties and potential uses of Uvadex.","approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Uvadex's mechanism of action is not well-documented, but it is likely to involve the modulation of a specific molecular pathway or target, which would require further research to elucidate."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=uvadex","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=uvadex","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:39:17.608704","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:23:25.567997+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[],"genericName":"uvadex","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04870437","phase":"NA","title":"Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation.","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2022-04-27","conditions":["Kidney Transplantation"],"enrollment":30,"completionDate":"2026-10-27"},{"nctId":"NCT06836648","phase":"","title":"Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer","status":"AVAILABLE","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT04389281","phase":"PHASE1","title":"X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma","status":"RECRUITING","sponsor":"Immunolight, LLC","startDate":"2021-12-08","conditions":["Advanced Solid Tumor Cancer"],"enrollment":52,"completionDate":"2029-03"},{"nctId":"NCT05157581","phase":"","title":"Extracorporeal Photopheresis in Sezary Syndrome","status":"RECRUITING","sponsor":"Oleg E. Akilov, MD, PhD","startDate":"2023-04-04","conditions":["Sezary Syndrome"],"enrollment":20,"completionDate":"2028-12"},{"nctId":"NCT06646016","phase":"PHASE2","title":"EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis","status":"WITHDRAWN","sponsor":"Therakos LLC","startDate":"2025-12-15","conditions":["Immune-related Colitis"],"enrollment":0,"completionDate":"2027-02-19"},{"nctId":"NCT03204721","phase":"NA","title":"Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-06-21","conditions":["Graft-Versus-Host Disease"],"enrollment":158,"completionDate":"2021-04-30"},{"nctId":"NCT05680558","phase":"PHASE2","title":"Photopheresis in Early-stage Mycosis Fungoides","status":"RECRUITING","sponsor":"Columbia University","startDate":"2021-05-08","conditions":["Cutaneous T Cell Lymphoma","Mycosis Fungoides"],"enrollment":74,"completionDate":"2027-07"},{"nctId":"NCT05718674","phase":"","title":"Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell Product","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-05-26","conditions":["Graft Vs Host Disease","Extracorporeal Photopheresis"],"enrollment":27,"completionDate":"2025-07-30"},{"nctId":"NCT02181257","phase":"PHASE3","title":"Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-01","conditions":["Bronchiolitis Obliterans Syndrome (BOS)"],"enrollment":280,"completionDate":"2028-12"},{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":["Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma"],"enrollment":502,"completionDate":"2025-02-05"},{"nctId":"NCT04291261","phase":"PHASE2","title":"Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-05-18","conditions":["Acute-graft-versus-host Disease"],"enrollment":24,"completionDate":"2025-06"},{"nctId":"NCT04986605","phase":"PHASE2","title":"Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2025-07-01","conditions":["Diffuse Cutaneous Systemic Sclerosis"],"enrollment":15,"completionDate":"2027-07"},{"nctId":"NCT03778996","phase":"PHASE2","title":"SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2020-01-03","conditions":["Sarcoma, Ewing","Sarcoma"],"enrollment":31,"completionDate":"2028-03-31"},{"nctId":"NCT00179855","phase":"PHASE2,PHASE3","title":"Extracorporeal Photopheresis for Acute Graft Versus Host Disease","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2003-07","conditions":["Graft Versus Host Disease","Cancer","Stem Cell Transplantation"],"enrollment":10,"completionDate":"2010-08"},{"nctId":"NCT05333367","phase":"NA","title":"MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-04-15","conditions":["Cutaneous T-Cell Lymphoma","Graft Vs Host Disease","Graft Rejection"],"enrollment":20,"completionDate":"2025-07"},{"nctId":"NCT03512756","phase":"PHASE2,PHASE3","title":"A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Tyme, Inc","startDate":"2018-03-27","conditions":["Pancreatic Cancer"],"enrollment":130,"completionDate":"2021-12-28"},{"nctId":"NCT05721079","phase":"NA","title":"Extracorporeal Photopheresis (ECP) After Lung Transplantation","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-03-01","conditions":["Lung Transplant Infection","Lung Transplant Rejection"],"enrollment":62,"completionDate":"2022-12-31"},{"nctId":"NCT05882331","phase":"NA","title":"Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19","status":"COMPLETED","sponsor":"Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases","startDate":"2021-01-01","conditions":["COVID-19"],"enrollment":7,"completionDate":"2024-08-06"},{"nctId":"NCT06133192","phase":"PHASE2","title":"Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2024-01","conditions":["Graft Vs Host Disease"],"enrollment":42,"completionDate":"2026-01"},{"nctId":"NCT04720664","phase":"PHASE2","title":"Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2021-09-22","conditions":["Breast Cancer","Metastatic Breast Cancer","Hormone Receptor Positive Breast Carcinoma"],"enrollment":11,"completionDate":"2023-02-10"},{"nctId":"NCT04414735","phase":"NA","title":"Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":["Kidney Transplant Rejection"],"enrollment":30,"completionDate":"2025-12"},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":["Leukemia","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasms"],"enrollment":17,"completionDate":"2014-09"},{"nctId":"NCT03109353","phase":"PHASE1,PHASE2","title":"Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2017-09-20","conditions":["Cutaneous T-Cell Lymphoma, Unspecified","Chronic Graft Versus Host Disease in Skin"],"enrollment":7,"completionDate":"2022-12-31"},{"nctId":"NCT03563040","phase":"PHASE2","title":"Study of Photopheresis in the Treatment of Erythrodermic MF and SS","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2020-12-01","conditions":["Lymphoma, T-Cell, Cutaneous","Mycosis Fungoides/Sezary Syndrome"],"enrollment":0,"completionDate":"2026-06-01"},{"nctId":"NCT04792294","phase":"","title":"Multicenter Analysis of Efficacy and Outcomes of Extracorporeal Photopheresis as Treatment of Chronic Lung Allograft Dysfunction","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2005-01-01","conditions":["Lung Transplant Rejection"],"enrollment":800,"completionDate":"2021-12-31"},{"nctId":"NCT02524847","phase":"PHASE3","title":"Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease","status":"TERMINATED","sponsor":"Therakos, Inc., a Mallinckrodt Company","startDate":"2016-01-20","conditions":["Steroid Refractory Acute Graft Versus Host Disease"],"enrollment":29,"completionDate":"2019-07-16"},{"nctId":"NCT02322190","phase":"PHASE2","title":"Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-20","conditions":["Chronic Graft vs. Host Disease","Graft vs Host Disease","Graft-Versus-Host Disease"],"enrollment":5,"completionDate":"2019-10-31"},{"nctId":"NCT01380535","phase":"EARLY_PHASE1","title":"Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2011-11","conditions":["Chronic Graft Versus Host Disease"],"enrollment":60,"completionDate":"2015-03"},{"nctId":"NCT02296346","phase":"NA","title":"Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis","status":"TERMINATED","sponsor":"University of Utah","startDate":"2014-10","conditions":["Secondary Progressive Multiple Sclerosis"],"enrollment":13,"completionDate":"2018-05-10"},{"nctId":"NCT02796898","phase":"PHASE1,PHASE2","title":"Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Tyme, Inc","startDate":"2016-06","conditions":["Prostate Cancer","Rising Prostate Specific Antigen (PSA)"],"enrollment":23,"completionDate":"2019-05-30"},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":["Lymphoma"],"enrollment":7,"completionDate":"2011-12"},{"nctId":"NCT01686594","phase":"PHASE3","title":"PUVA Maintenance Therapy in Mycosis Fungoides","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2013-02","conditions":["Patch/Plaque Stage Mycosis Fungoides"],"enrollment":28,"completionDate":"2018-07-02"},{"nctId":"NCT00005092","phase":"PHASE1","title":"Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1999-05-28","conditions":["Leukemia","Lymphoma","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes"],"enrollment":7,"completionDate":"2002-08-28"},{"nctId":"NCT00221039","phase":"PHASE4","title":"Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-04-02","conditions":["Cutaneous T Cell Lymphoma","Mycosis Fungoides"],"enrollment":7,"completionDate":"2011-04-05"},{"nctId":"NCT03605940","phase":"PHASE2","title":"A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2018-10-01","conditions":["Acute-graft-versus-host Disease"],"enrollment":78,"completionDate":"2022-04-01"},{"nctId":"NCT00056056","phase":"PHASE3","title":"Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-01","conditions":["Lymphoma"],"enrollment":93,"completionDate":"2011-06"},{"nctId":"NCT00054613","phase":"PHASE2","title":"Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2002-06","conditions":["Graft-versus-Host Disease"],"enrollment":72,"completionDate":"2004-03"},{"nctId":"NCT00282503","phase":"PHASE3","title":"Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2006-01","conditions":["Acute Graft-versus-Host Disease"],"enrollment":19,"completionDate":""},{"nctId":"NCT00054600","phase":"PHASE2","title":"Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2002-06","conditions":["Graft-versus-Host Disease"],"enrollment":60,"completionDate":"2004-06"},{"nctId":"NCT00639717","phase":"PHASE2","title":"Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-03","conditions":["Graft Versus Host Disease"],"enrollment":48,"completionDate":"2016-04"},{"nctId":"NCT01824368","phase":"PHASE1,PHASE2","title":"Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.","status":"COMPLETED","sponsor":"Red de Terapia Celular","startDate":"2013-04","conditions":["Liver Transplantation","Immunosuppression"],"enrollment":10,"completionDate":"2016-04"},{"nctId":"NCT03083574","phase":"PHASE2","title":"Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)","status":"UNKNOWN","sponsor":"Jules Bordet Institute","startDate":"2014-09","conditions":["Refractory Chronic Graft Versus Host Disease (cGVHD)"],"enrollment":100,"completionDate":"2023-09"},{"nctId":"NCT00402714","phase":"PHASE2","title":"A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-07","conditions":["Hematologic Malignancies"],"enrollment":14,"completionDate":"2009-08"},{"nctId":"NCT01174940","phase":"EARLY_PHASE1","title":"Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2010-06","conditions":["Stem Cell Leukemia of Unclear Lineage","Graft Versus Host Disease"],"enrollment":22,"completionDate":"2015-08"},{"nctId":"NCT00221000","phase":"PHASE2","title":"Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2003-08","conditions":["Rheumatoid Arthritis"],"enrollment":86,"completionDate":"2006-11"},{"nctId":"NCT00221026","phase":"PHASE2","title":"Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2004-12","conditions":["Crohn's Disease"],"enrollment":25,"completionDate":"2006-06"},{"nctId":"NCT02631993","phase":"","title":"Photochemotherapy and Graft-versus-leukemia in Acute-leukemia","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2014-10","conditions":["ALL","AML","Acute GVHD","Tumor Immunity"],"enrollment":47,"completionDate":"2014-12"},{"nctId":"NCT02090621","phase":"PHASE2","title":"Extracorporeal Photopheresis After Liver Transplant","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2012-10","conditions":["Hepatic Insufficiency"],"enrollment":10,"completionDate":"2015-03"},{"nctId":"NCT01559584","phase":"NA","title":"Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2012-03","conditions":["Alopecia Areata"],"enrollment":40,"completionDate":"2014-03"},{"nctId":"NCT01402414","phase":"NA","title":"Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis","status":"TERMINATED","sponsor":"Ruhr University of Bochum","startDate":"2011-04","conditions":["Atopic Dermatitis"],"enrollment":10,"completionDate":"2014-02"},{"nctId":"NCT00157027","phase":"PHASE1","title":"RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)","status":"WITHDRAWN","sponsor":"Atlantic Health System","startDate":"2003-12","conditions":["HIV Infections"],"enrollment":0,"completionDate":"2010-04"},{"nctId":"NCT00265603","phase":"PHASE1","title":"Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Atlantic Health System","startDate":"2004-10","conditions":["Non-Small Cell Lung Cancer"],"enrollment":16,"completionDate":"2009-04"},{"nctId":"NCT00030589","phase":"PHASE2","title":"Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma","status":"UNKNOWN","sponsor":"Millennix","startDate":"2001-02","conditions":["Lymphoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT00930566","phase":"PHASE1,PHASE2","title":"Extracorporal Photopheresis Pilot Study","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2009-04","conditions":["Hematological Malignancies"],"enrollment":20,"completionDate":"2015-09"},{"nctId":"NCT00811005","phase":"PHASE3","title":"Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2008-10","conditions":["Pustular Palmoplantar Psoriasis"],"enrollment":20,"completionDate":"2010-10"},{"nctId":"NCT00533195","phase":"PHASE3","title":"Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":["Atopic Dermatitis"],"enrollment":20,"completionDate":"2009-01"},{"nctId":"NCT00630903","phase":"PHASE4","title":"PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides","status":"TERMINATED","sponsor":"Madrilenian Group of Cutaneous Lymphomas","startDate":"2000-01","conditions":["Cutaneous T-Cell Lymphoma (Mycosis Fungoides)"],"enrollment":54,"completionDate":""},{"nctId":"NCT00056355","phase":"PHASE1","title":"Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-03","conditions":["Crohn Disease"],"enrollment":10,"completionDate":"2005-11"},{"nctId":"NCT00004359","phase":"PHASE2","title":"Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1996-02","conditions":["Epidermolysis Bullosa Acquisita"],"enrollment":10,"completionDate":""},{"nctId":"NCT00002011","phase":"NA","title":"The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex","status":"COMPLETED","sponsor":"Therakos","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL416"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","relationship":"Original Developer"}],"publicationCount":7,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"UVADEX","companyName":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","companyId":"london-health-sciences-centre-research-institute-or-lawson-research-institute-of-st-joseph-s","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:23:25.567997+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}